Efficacy and Safety of Pioglitazone in Treatment of a Patient with an Atypical Partial Lipodystrophy Syndrome

Lipodystrophies and Dyslipidemias

“…Similar improvement in serum lipids have been reported anecdotally in a few FPLD patients with both rosiglitazone [76] and pioglitazone [77,78], though some case reports suggest worsening of dyslipidemia [79]. Interestingly, we recently noted that thiazolidinediones do not reverse fat loss in patients with FPLD, and in fact may worsen excess deposition in nonlipodystrophic regions [80].…”

Premature Atherosclerosis in a Japanese Diabetic Patient with Atypical Familial Partial Lipodystrophy and Hypertriglyceridemia

“…Although the effects of thiazolidinediones on glycemic control appear to vary in patients with FPL (11,17,(22)(23)(24)(25)(26), pioglitazone treatment decreased the levels of HbA1c and fasting TG in the case of Patient 1. It is conceivable that pioglitazone improves glycemic control and triglycemic control by reducing the levels of free fatty acids (FFA) in venous effluent from adipose tissue and by limiting the lipotoxicity of other insulin-sensitive tissues, e.g.…”

GENETICS IN ENDOCRINOLOGY: Genetic forms of severe insulin resistance: what endocrinologists should know

“…Metformin is best established and should be titrated to the maximum tolerated dose. Thiazolidinediones may sometimes be effective[40][41][42], but the best available evidence suggests that they require residual adipose depots to achieve metabolic benefit[43], and this may occur at the expense of expansion of cosmetically distressing depots such as those in the head and neck. Thus they should be used only with caution.…”